Revolution Medicines, Inc. announced on October 25, 2024, preliminary safety and antitumor data for RMC-9805, its RAS(ON) G12D-selective inhibitor, in patients with previously treated pancreatic ductal adenocarcinoma (PDAC). These initial results were presented during a late-breaking oral session at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
The RMC-9805-001 Phase 1/1b study, which included 179 patients with advanced solid tumors harboring a KRAS G12D mutation, demonstrated an encouraging safety profile. The most common treatment-related adverse events were primarily Grade 1 GI-related toxicities and rash, with only one Grade 3 ALT elevation and no Grade 4 or 5 events observed.
Preliminary efficacy in PDAC patients at a 1200 mg daily dose showed a 30% objective response rate (confirmed or pending) and an 80% disease control rate among 40 evaluable patients. These data mark RMC-9805 as the third tri-complex compound from Revolution Medicines' pipeline to demonstrate clinical proof-of-concept, highlighting its potential in a cancer with significant unmet need.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.